|
Delayed
Hong Kong S.E.
12:08:27 30/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.4500 HKD | -5.26% |
|
+20.00% | -10.00% |
| 08-28 | Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 06-24 | Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection) | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MABPHARM LIMITED | Bio Therapeutic Drugs | -5.26% | +20.00% | -10.00% | -28.57% | -51.09% | 250M |  |  |  |
- Stock Market
- Stocks
- 2181 Stock
- Charts Mabpharm Limited
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
